Trial Profile
Observation of the Effect of Chemotherapy Combined With Tyrosinase Inhibitor on the Reactivation of CMV and EBV in Patients With Acute Lymphoblastic Leukemia
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 30 Jun 2023
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Imatinib (Primary) ; Nilotinib (Primary) ; Ponatinib (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 08 Nov 2017 New trial record
- 07 Nov 2017 Status changed from active, no longer recruiting to recruiting.